Efficacy of helical tomotherapy combined with CT-guided three-dimensional intracavitary brachytherapy in treatment of locally advanced cervical cancer
Ye X, Ye P, Zheng Y, Xia W | J BUON | 2021
The prognostic significance of pretreatment squamous cell carcinoma antigen levels in cervical cancer patients treated by concurrent chemoradiation therapy and a comparison of dosimetric outcomes and clinical toxicities between TomoTherapy and volumetric modulated arc therapy
Cheng YK, Kuo SH, Yen HH, Wu JH, Chen YC, and Huang MY | Radiat Oncol | 2022
Comparing dosimetric and cancer control outcomes after intensity-modulated radiation therapy and TomoTherapy for advanced cervical cancer
Li D, Wang D, Feng S, Chen Q, Sheng X, Jia J, Yan X, Zhu J, and Yin Y | Oncol Lett | 2022
High-dose radiotherapy with helical tomotherapy and long-term androgen deprivation therapy for prostate cancer: 5-year outcomes
Tomita N, Soga N, Ogura Y, Hayashi N, Kageyama T, Ito M, Koide Y, Yoshida M, Kimura K, Makita C, Tachibana H, Kodaira T | J Cancer Res Clin Oncol | 2016
Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a Phase I-II Study
Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, Valdagni R, Dell’Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, Briganti A, Calandrino R, Cozzarini C, Fiorino C | Clin Oncol | 2016
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
Yamazaki H, Masui K, Suzuki G, Nakamura S, Shimizu D, Nishikawa T, Okabe H, Yoshida K, Kotsuma T, Tanaka E, Otani K, Yoshioka Y, Ogawa K | Cancers (Basel) | 2018
Intensity-Modulated Radiation Therapy with Simultaneous Integrated Boost for Clinically Node-Positive Prostate Cancer: A Single-Institutional Retrospective Study
Onishi M, Kawamura H, Murata K, Inoue T, Murata H, Takakusagi Y, Okonogi N, Ohkubo Y, Okamoto M, Kaminuma T, Sekihara T, Nakano T, Ohno T | Cancers (Basel) | 2021
Post-operative hypofractionated radiotherapy for prostate cancer: a mono-institutional analysis of toxicity and clinical outcomes
Ferrera G, D’Alessandro S, Cuccia F, Serretta V, Trapani G, Savoca G, Mortellaro G, Lo Casto A | J Cancer Res Clin Oncol | 2022
Moderate Hypofractionated Helical TomoTherapy for Older Patients with Localized Prostate Cancer: Long-term Outcomes of a Phase I-II Trial
Cui D, Du L, Yu W, Cai B, Meng L, Yang J, Luo Y, Chen J, and Ma L | Radiol Oncol| 2022
Adaptive Radiotherapy for Carcinoma of the Urinary Bladder: Long-term Outcomes With Dose Escalation
Murthy V, Gupta P, Baruah K, Krishnatry R, Joshi A, Prabhash K, Noronha V, Menon S, Pal M, Prakash G, Bakshi G | Clin Oncol | 2019
Ultra-hypofractionated radiation therapy for unfavourable intermediate-risk and high-risk prostate cancer is safe and effective: 5-year outcomes of a phase II trial
Macias VA, Barrera-Mellado I | BJU Int | 2020
Phase I Trial of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Ablative Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer
Kunos CA, Sherertz TM, Mislmani M, Ellis RJ, Lo SS, Waggoner SE, Zanotti KM, Herrmann K, Debernardo RL | Front Oncol | 2015
Stereotactic Body Radiotherapy for Recurrent or Oligometastatic Uterine Cervix Cancer: A Cooperative Study of the Korean Radiation Oncology Group (KROG 14-11)
Park HJ, Chang AR, Seo Y, Cho CK, Jang WI, Kim MS, Choi C | Anticancer Res | 2015
Stereotactic Radiotherapy in the Retreatment of Recurrent Cervical Cancers, Assessment of Toxicity, and Treatment Response: Initial Results and Literature Review
Pontoriero A, Iatì G, Aiello D, Pergolizzi S | Technol Cancer Res Treat | 2016
Long-term results of robotic radiosurgery for non brachytherapy patients with cervical cancer
Morgenthaler J, Köhler C, Budach V, Sehouli J, Stromberger C, Besserer A, Trommer M, Baues C, Marnitz S | Strahlenther Onkol | 2021
CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers
Kataria T, Naga P, Banerjee S, Gupta D, Narang K, Tayal M, Bisht SS | South Asian J Cancer | 2021
Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints
Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. | Int J Radiat Oncol Biol Phys | 2018
Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial
Wang K, Chen RC, Kane B, Medbery CA, Underhill K, Gray JR, Peddada AV, Fuller DB | Int J Radiat Oncol Biol Phys | 2018
5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer
Blacksburg SR, Aghdam N, Royce TJ, Burri RJ, Obayomi-Davies O, Mezeckis M, Meier R, Fuller DB, Chen RC, Lanciano RM, Haas JA, Collins SP | Int J Radiat Oncol Biol Phys | 2019
Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van […]
